Explore Video

Two Clinical Trials with long term follow up (LATITIDUE 52 Months) & STAMEPDE (72 Months) have confirmed effectiveness of Abiraterone in mHSPC.

Modern Web -Based digital tools based on 10 routinely used clinical parameters and Gradient Based Model can help in non-invasive diagnosis of MDS.

In patients with renal impairment primary goal is improvement of Renal Function which is associated with improved treatment outcomes. 50% of patients present renal impairment and renal impairment is severe in 15% of patients.

Major cardiovascular toxicities associated with the prostate cancer treatment include arrhythmias, atherosclerosis, myocardial Infarction, hypertension & cardiomyopathy. Toxicities vary with the type of agent used in Prostate Cancer Treatment.

Bone marrow examination-based diagnosis of MDS with either biopsy or aspirate remains standard of care but is associated with pain, bleeding, difficulty to use the same in elderly patients and hIgh interobserver variability.

Tumors with a HER-2 immunohistochemistry (IHC) score of 1 + or 2 + and a negative molecular reflex test have been classified as HER2-low Breast Cancers.

Best evidence for Lenalidomide maintenance after ASCT came from Meta-analysis of 3 trials (McCarthy et al, JCO 207) confirmed significant OS benefit with Lenalidomide maintenance.

ESR1 mutation leads to ligand independent activation of estrogen receptor. ESR1 mutations were first described in 1997 & their role remain underestimated as initial research was focused on primary tumor wherein these mutations were absent.

Immune cells known as tumor-infiltrating lymphocytes (TILs) are thought to be a promising, affordable biomarker with prognostic and predictive potential.

In this video, Dr. Floege talks about the mechanisms of vascular calcifications in patients at high risk of CKD and measures to prevent or reverse the same.